PIK3CB and prostate cancer: The functional characterization of a PIK3CB catalytic domain mutant, p110βE1051K, first discovered by others in castrate-resistant prostate cancer (mCRPC), is outlined in this report; our data suggest that p110βE1051K is a gain-of-function mutation, driving PI3K signaling, tumorigenic cell growth and migration.